ursodeoxycholic acid
AssetSmall moleculeAlso UDCA
Bile acid that decreases intestinal cholesterol absorption and protects hepatocytes
- Stage
- Approved
- Modality
- Small molecule
- Target
- Apoptosis
- Indications
- 4
- Trials
- 74
- Developers
- 2
Indications
4Primary biliary cholangitis
Approvedaccessdata.fda.gov7 Oct 2026
Systemic disease
Approvedaccessdata.fda.gov7 Oct 2026
Chronic hepatitis c
Phase 3COMPLETEDNCT00200343clinicaltrials.gov7 Oct 2026
1 more
- Targets and what it contains3
- Owner and partners2
- Trials74
- Evidence for its targets3
- Competitors3
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 6 sources